Nextkidney raises €20M to ready its portable dialysis device for market
What's the deal? Dutch medtech firm Nextkidney has raised more than €20 million in a Series C round to complete development of the Neokidney, a portable hemodialysis device, and prepare it for market. It is also running a crowdfunding campaign via Invesdor seeking an additional €3 million, with support from Generous MindsDealroom has a profile for this one. Try Dealroom →.
The product: The Neokidney aims to move dialysis out of the hospital and into the home. Conventional dialysis typically takes around four hours per treatment, three times a week; the device is designed to let patients dialyze independently, wherever and whenever they need.
Where it stands: After more than a decade of development, Nextkidney reports 500 completed treatments across four medical centres in the Netherlands, Belgium, and France, including university medical centres in Utrecht and Leiden. Starting this month, it will launch a study in which patients perform 500 treatments independently outside the hospital.
What's next? Subject to CE marking and FDA approval, Nextkidney plans a first commercial introduction for clinical use at the end of 2027, with home use on the European market targeted for Q1 2028.
Why now? The clinical results give the company a basis to move toward broader use. "The 500 completed treatments demonstrate that the Neokidney is ready for the next step toward broader clinical use and, ultimately, home dialysis," said Dieter Bach, chief medical officer at Nextkidney.
Who's backing it? The round drew investors including 3O Health. "Combined with the potential to reduce dialysis costs, we see Nextkidney as a valuable investment," said Jan Otto Ooms of 3O Health. Dutch health insurers CZ, Menzis, and Zilveren Kruis are also involved.
What could go wrong? The device still lacks CE marking and FDA clearance, and home use has not yet been validated. The proposed launch timeline depends on hitting those clinical and regulatory milestones.
The signal: Nextkidney, which originated from the Dutch Kidney Foundation, is betting on portability in a field where established dialysis makers are pushing to make treatment more accessible at home. For now the company has an unproven product rather than a market-ready product — but investor and insurer backing signals confidence that home dialysis is where the market is heading.
Read more: nextkidney.com
Image credit: Nextkidney
